Skip to main content

Illumina CEO Sold $3.3M Worth of Company Stock Since Start of 2006

NEW YORK (GenomeWeb News) - Illumina CEO Jay Flatley sold 2,500 shares of the company's stock at $35.04 apiece for total proceeds of $87,600 on Aug. 10, according to documents filed with the Securities and Exchange Commission on Monday.
 
He sold 14,000 shares this month before last week's transaction for total proceeds of $515,466. He currently owns 647,998 shares of Ilumina stock.
 
Shares in Illumina were down 6.8 percent, or $2.34, to $32.09 in mid-afternoon trading today. 
 
Flatley has sold 119,500 shares since the beginning of the year, pocketing almost $3.3 million in proceeds.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.